Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1990 Mar;69(3):396–401.

Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells.

T Hideshima 1, N Okada 1, H Okada 1
PMCID: PMC1385958  PMID: 1690178

Abstract

HRF20 is a homologous restriction factor of 20,000 MW that prevents cells from membrane attack by homologous complement. HRF20 has been identified by a monoclonal antibody (mAb), 1F5, and is one of the phosphatidylinositol(PI)-anchored cell-surface glycoproteins. We analysed the distribution of HRF20 expressed on subsets of peripheral blood lymphocytes using 1F5. HRF20 is expressed in relatively large amounts on T cells. In contrast, adherent cells possess smaller amounts of HRF20 while having large quantities of decay-accelerating factor (DAF). Although DAF was shown to be deficient or present at rather low levels on NK cells, HRF20 was detected in 95% of large granular lymphocytes (LGL), as described by FACS analysis. We also determined the effect of 1F5 on both mononuclear leucocytes and T cells in terms of their growth response. The results show that 1F5 induces T-cell proliferation when cells are stimulated with interleukin-2 (IL-2). In addition, induction of proliferation is facilitated by cross-linking 1F5 with a second antibody. These results suggest that HRF20 expressed on T cells not only protects them from cytotoxic attack by homologous complement, but also may initiate intracellular signals leading to cell activation when they happen to be cross-linked.

Full text

PDF
396

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bockenstedt L. K., Goldsmith M. A., Dustin M., Olive D., Springer T. A., Weiss A. The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor. J Immunol. 1988 Sep 15;141(6):1904–1911. [PubMed] [Google Scholar]
  2. Davis L. S., Patel S. S., Atkinson J. P., Lipsky P. E. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol. 1988 Oct 1;141(7):2246–2252. [PubMed] [Google Scholar]
  3. Davitz M. A., Low M. G., Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med. 1986 May 1;163(5):1150–1161. doi: 10.1084/jem.163.5.1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fujita T., Inoue T., Ogawa K., Iida K., Tamura N. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med. 1987 Nov 1;166(5):1221–1228. doi: 10.1084/jem.166.5.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Groscurth P., Qiao B. Y., Podack E. R., Hengartner H. Cellular localization of perforin 1 in murine cloned cytotoxic T lymphocytes. J Immunol. 1987 May 1;138(9):2749–2752. [PubMed] [Google Scholar]
  6. Gunter K. C., Germain R. N., Kroczek R. A., Saito T., Yokoyama W. M., Chan C., Weiss A., Shevach E. M. Thy-1-mediated T-cell activation requires co-expression of CD3/Ti complex. Nature. 1987 Apr 2;326(6112):505–507. doi: 10.1038/326505a0. [DOI] [PubMed] [Google Scholar]
  7. Holter W., Majdic O., Stockinger H., Knapp W. Analysis of T cell activation with a non-mitogenic anti CD3 antibody and the phorbol ester TPA. Clin Exp Immunol. 1985 Dec;62(3):600–606. [PMC free article] [PubMed] [Google Scholar]
  8. Hänsch G. M., Weller P. F., Nicholson-Weller A. Release of C8 binding protein (C8bp) from the cell membrane by phosphatidylinositol-specific phospholipase C. Blood. 1988 Sep;72(3):1089–1092. [PubMed] [Google Scholar]
  9. Hünig T., Tiefenthaler G., Meyer zum Büschenfelde K. H., Meuer S. C. Alternative pathway activation of T cells by binding of CD2 to its cell-surface ligand. Nature. 1987 Mar 19;326(6110):298–301. doi: 10.1038/326298a0. [DOI] [PubMed] [Google Scholar]
  10. Jung G., Martin D. E., Müller-Eberhard H. J. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. J Immunol. 1987 Jul 15;139(2):639–644. [PubMed] [Google Scholar]
  11. Kroczek R. A., Gunter K. C., Germain R. N., Shevach E. M. Thy-1 functions as a signal transduction molecule in T lymphocytes and transfected B lymphocytes. Nature. 1986 Jul 10;322(6075):181–184. doi: 10.1038/322181a0. [DOI] [PubMed] [Google Scholar]
  12. Kroczek R. A., Gunter K. C., Seligmann B., Shevach E. M. Induction of T cell activation by monoclonal anti-Thy-1 antibodies. J Immunol. 1986 Jun 15;136(12):4379–4384. [PubMed] [Google Scholar]
  13. Lichtenheld M. G., Olsen K. J., Lu P., Lowrey D. M., Hameed A., Hengartner H., Podack E. R. Structure and function of human perforin. Nature. 1988 Sep 29;335(6189):448–451. doi: 10.1038/335448a0. [DOI] [PubMed] [Google Scholar]
  14. MacDonald H. R., Bron C., Rousseaux M., Horvath C., Cerottini J. C. Production and characterization of monoclonal anti-Thy-1 antibodies that stimulate lymphokine production by cytolytic T cell clones. Eur J Immunol. 1985 May;15(5):495–501. doi: 10.1002/eji.1830150514. [DOI] [PubMed] [Google Scholar]
  15. Malek T. R., Ortega G., Chan C., Kroczek R. A., Shevach E. M. Role of Ly-6 in lymphocyte activation. II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies. J Exp Med. 1986 Sep 1;164(3):709–722. doi: 10.1084/jem.164.3.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Manger B., Weiss A., Imboden J., Laing T., Stobo J. D. The role of protein kinase C in transmembrane signaling by the T cell antigen receptor complex. Effects of stimulation with soluble or immobilized CD3 antibodies. J Immunol. 1987 Oct 15;139(8):2755–2760. [PubMed] [Google Scholar]
  17. Martin D. E., Zalman L. S., Jung G., Müller-Eberhard H. J. Induction of synthesis of the cytolytic C9 (ninth component of complement)-related protein in human peripheral mononuclear cells by monoclonal antibody OKT3 or interleukin 2: correlation with cytotoxicity and lymphocyte phenotype. Proc Natl Acad Sci U S A. 1987 May;84(9):2946–2950. doi: 10.1073/pnas.84.9.2946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Meuer S. C., Hussey R. E., Fabbi M., Fox D., Acuto O., Fitzgerald K. A., Hodgdon J. C., Protentis J. P., Schlossman S. F., Reinherz E. L. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell. 1984 Apr;36(4):897–906. doi: 10.1016/0092-8674(84)90039-4. [DOI] [PubMed] [Google Scholar]
  19. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
  20. Nicholson-Weller A., Russian D. A., Austen K. F. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF). J Immunol. 1986 Aug 15;137(4):1275–1279. [PubMed] [Google Scholar]
  21. Okada N., Harada R., Fujita T., Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol. 1989;1(2):205–208. doi: 10.1093/intimm/1.2.205. [DOI] [PubMed] [Google Scholar]
  22. Okada N., Harada R., Fujita T., Okada H. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J Immunol. 1989 Oct 1;143(7):2262–2266. [PubMed] [Google Scholar]
  23. Pantaleo G., Olive D., Poggi A., Kozumbo W. J., Moretta L., Moretta A. Transmembrane signalling via the T11-dependent pathway of human T cell activation. Evidence for the involvement of 1,2-diacylglycerol and inositol phosphates. Eur J Immunol. 1987 Jan;17(1):55–60. doi: 10.1002/eji.1830170110. [DOI] [PubMed] [Google Scholar]
  24. Reiser H., Oettgen H., Yeh E. T., Terhorst C., Low M. G., Benacerraf B., Rock K. L. Structural characterization of the TAP molecule: a phosphatidylinositol-linked glycoprotein distinct from the T cell receptor/T3 complex and Thy-1. Cell. 1986 Nov 7;47(3):365–370. doi: 10.1016/0092-8674(86)90593-3. [DOI] [PubMed] [Google Scholar]
  25. Schönermark S., Rauterberg E. W., Shin M. L., Löke S., Roelcke D., Hänsch G. M. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol. 1986 Mar 1;136(5):1772–1776. [PubMed] [Google Scholar]
  26. Timonen T., Ortaldo J. R., Herberman R. B. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981 Mar 1;153(3):569–582. doi: 10.1084/jem.153.3.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ting C. C., Hargrove M. E., Yun Y. S. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. J Immunol. 1988 Aug 1;141(3):741–748. [PubMed] [Google Scholar]
  28. Young J. D., Hengartner H., Podack E. R., Cohn Z. A. Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell. 1986 Mar 28;44(6):849–859. doi: 10.1016/0092-8674(86)90007-3. [DOI] [PubMed] [Google Scholar]
  29. Zalman L. S., Brothers M. A., Chiu F. J., Müller-Eberhard H. J. Mechanism of cytotoxicity of human large granular lymphocytes: relationship of the cytotoxic lymphocyte protein to the ninth component (C9) of human complement. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5262–5266. doi: 10.1073/pnas.83.14.5262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zalman L. S., Wood L. M., Müller-Eberhard H. J. Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes. J Exp Med. 1987 Oct 1;166(4):947–955. doi: 10.1084/jem.166.4.947. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES